1 |
熊成龙, 蒋露芳, 姜庆五. β-冠状病毒引起人类疾病的流行与控制[J]. 上海预防医学, 2020, 32(1): 58-66.
|
2 |
GEORGAKOPOULOU V E, PETSINIS G, MANTZOURANIS K, et al. First detection of human coronavirus HKU1 in Greece, in an immunocompromised patient with severe lower respiratory tract infection[J].Acta Med Litu,2021,28(1): 121-126.
|
3 |
唐玫琴, 涂传清, 田发青, 等. 利妥昔单抗辅助CHOP方案治疗B细胞型非霍奇金淋巴瘤的可行性分析[J]. 中国现代药物应用, 2018, 12(15): 99-100.
|
4 |
沈 磊, 张伊莉, 卞建军, 等. 利妥昔单抗配合CHOP化疗对非霍奇金淋巴瘤患者血清TK-1、VEGF的影响[J]. 国际检验医学杂志, 2018, 39(5): 602-605.
|
5 |
张 呈, 苏铭俊, 容庭杰, 等. R-GEMOX方案治疗复发难治B细胞性非霍奇金淋巴瘤的疗效[J]. 现代肿瘤医学, 2018, 26(24): 4008-4010.
|
6 |
SEHN L H, MARTELLI M, TRNĚNÝ M, et al. A randomized, open-label, Phase Ⅲ study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA[J]. J Hematol Oncol, 2020, 13(1): 71.
|
7 |
MONDELLO P, MIAN M. Frontline treatment of diffuse large B-cell lymphoma: beyond R-CHOP[J]. Hematol Oncol, 2019, 37(4): 333-344.
|
8 |
田普训, 敖建华, 李 宁, 等. 器官移植免疫抑制剂临床应用技术规范(2019版)[J]. 器官移植,2019, 10(3): 213-226.
|
9 |
杨秋媚. 常用免疫抑制剂及其免疫抑制机理概述[J]. 生物学教学, 2019, 44(7): 2-3.
|
10 |
RAMOS-CASALS M, BRAHMER J R, CALLAHAN M K, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38.
|
11 |
陈 康, 孙步彤. PD-1/PD-L1抑制剂在晚期肿瘤患者中的相关肺炎发生率和发生风险:一项荟萃分析[J]. 中国肺癌杂志, 2020, 23(11): 927-940.
|
12 |
SURESH K, NAIDOO J, LIN C T, et al. Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities[J]. Chest, 2018, 154(6): 1416-1423.
|
13 |
LAU S K P, WOO P C Y, YIP C C Y, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong[J]. J Clin Microbiol, 2006, 44(6): 2063-2071.
|
14 |
孙 洁, 聂 炜, 黄 艳, 等. 贵州省1例人类冠状病毒HKU1感染死亡病例流行病学调查[J]. 中国公共卫生, 2020, 36(2): 246-249.
|
15 |
KANWAR A, SELVARAJU S, ESPER F. Human coronavirus-HKU1 infection among adults in Cleveland, Ohio[J]. Open Forum Infect Dis, 2017, 4(2): ofx052.
|
16 |
WOO P C, LAU S K, CHU C M, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia[J]. J Virol, 2005, 79(2): 884-895.
|
17 |
DOMINGUEZ S R, TRAVANTY E A, QIAN Z H, et al. Human coronavirus HKU1 infection of primary human type Ⅱ alveolar epithelial cells: cytopathic effects and innate immune response[J]. PLoS One,2013,8(7): e70129.
|
18 |
李 卓, 陈丽华. 冠状病毒感染的免疫应答及其致病机制研究进展[J]. 传染病信息, 2020, 33(1): 56-61.
|
19 |
杨柳柳, 詹少锋, 王 勇, 等. 肾病综合征并发肺孢子菌肺炎和巨细胞病毒性肺炎1例报告及文献复习[J]. 吉林大学学报(医学版), 2020, 46(3): 620-624.
|
20 |
李幸乐, 卢世栋, 马红霞, 等. 新型冠状病毒肺炎合并感染Ⅰ型单纯疱疹病毒的诊断[J]. 郑州大学学报(医学版), 2021,56(5): 731-733.
|
21 |
翁剑真, 李燕明. 重症肺炎免疫调节治疗:正反两面[J].中国实用内科杂志, 2022,42(3): 191-195.
|
22 |
SERZAN M T, KUMAR P N, ATKINS M B. Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy[J]. J Immunother Cancer, 2020,8(1): e000898.
|
23 |
EILAMI O, LOPES M I B F, GRYSCHEK R C B,et al.A case report of COVID-19 in a patient with non-Hodgkin’s lymphoma[J]. BMC Infect Dis,2021,21(1): 809.
|
24 |
CHALLENOR S, TUCKER D. SARS-CoV-2-induced remission of Hodgkin lymphoma[J]. Br J Haematol, 2021, 192(3): 415.
|
25 |
KURLAPSKI M, ROMANOWICZ G, TASZNER M, et al. SARS‑CoV‑2-induced remission of advanced classical Hodgkin lymphoma[J]. Pol Arch Intern Med, 2022, 132(7/8): 16266.
|
26 |
GWINN M, MACCANNELL D, ARMSTRONG G L. Next-generation sequencing of infectious pathogens[J]. JAMA, 2019, 321(9): 893-894.
|
27 |
GU W, MILLER S, CHIU C Y. Clinical metagenomic next-generation sequencing for pathogen detection[J]. Annu Rev Pathol, 2019, 14: 319-338.
|
28 |
GAUNT E R, HARDIE A, CLAAS E C, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method[J]. J Clin Microbiol, 2010, 48(8): 2940-2947.
|
29 |
WAN Z Z, ZHANG Y N, HE Z X, et al. A melting curve-based multiplex RT-qPCR assay for simultaneous detection of four human coronaviruses[J]. Int J Mol Sci, 2016, 17(11): E1880.
|
30 |
SHIBATA S, ISHIGURO T, KOBAYASHI Y, et al. High incidence of false-positive results of IgG antibody against SARS-CoV-2 with rapid immunochromatographic antibody test due to human common cold coronavirus infection[J]. Respir Med Case Rep, 2020, 31: 101180.
|
31 |
CHAUNG J, CHAN D, PADA S, et al. Coinfection with COVID-19 and coronavirus HKU1-The critical need for repeat testing if clinically indicated[J]. J Med Virol, 2020, 92(10): 1785-1786.
|